Record Information |
---|
Version | 2.0 |
---|
Created at | 2023-12-21 00:00:49 UTC |
---|
Updated at | 2024-09-03 04:18:33 UTC |
---|
NP-MRD ID | NP0332246 |
---|
Natural Product DOI | https://doi.org/10.57994/1432 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Ipriflavone |
---|
Description | Ipriflavone, also known as osten or FL-113, belongs to the class of organic compounds known as isoflavones. These are polycyclic compounds containing a 2-isoflavene skeleton which bears a ketone group at the C4 carbon atom. Ipriflavone has been described as a phytoestrogen. Ipriflavone is an extremely weak basic (essentially neutral) compound (based on its pKa). The drug prevents bone loss via mechanisms that are distinct from those of estrogens. A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers. A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis. Ipriflavone (INN, JAN; brand name Yambolap) is a synthetic isoflavone which may be used to inhibit bone resorption, maintain bone density and to prevent osteoporosis in postmenopausal women. However, this is incorrect, as the drug does not bind to or activate the estrogen receptor and shows no estrogenic effects in postmenopausal women. It is not used to treat osteoporosis. Ipriflavone was first documented in 2001 (PMID: 11255425). It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass (PMID: 23265084) (PMID: 17297162) (PMID: 21594876) (PMID: 24084576). |
---|
Structure | CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C1=CC=CC=C1 InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3 |
---|
Synonyms | Value | Source |
---|
7-(1-Methylethoxy)-3-phenyl-4H-1-benzopyran-4-one | ChEBI | 7-Isopropoxyisoflavone | ChEBI | FL-113 | ChEBI | Ipriflavona | ChEBI | Ipriflavonum | ChEBI | Iprosten | ChEBI | Osten | ChEBI | Yambolap | ChEBI | (Ipriflavone) | HMDB | 3-Phenyl-7-(propan-2-yloxy)-4H-chromen-4-one | HMDB | 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one | HMDB | FL113 | HMDB | Ipriflavone, inn | HMDB | Osteochin | HMDB | Osteofix | HMDB | Osteoquine | HMDB | Quinogin | HMDB |
|
---|
Chemical Formula | C18H16O3 |
---|
Average Mass | 280.3178 Da |
---|
Monoisotopic Mass | 280.10994 Da |
---|
IUPAC Name | 3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one |
---|
Traditional Name | osten |
---|
CAS Registry Number | Not Available |
---|
SMILES | CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C1=CC=CC=C1 |
---|
InChI Identifier | InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3 |
---|
InChI Key | SFBODOKJTYAUCM-UHFFFAOYSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
HSQC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-05-02 | View Spectrum | HMBC NMR | [1H, 13C] NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-05-02 | View Spectrum | COSY NMR | [1H, 1H] NMR Spectrum (2D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-05-02 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-05-02 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, CD3OD, experimental) | bgnzk@missouri.edu | MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-05-02 | View Spectrum |
| Predicted Spectra |
---|
|
| Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
---|
| Chemical Shift Submissions |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 600.133705802, CD3OD, simulated) | bgnzk@missouri.edu | Sumner Lab, MU Metabolomics Center, University of Missouri, Columbia. MO, USA | Dr. Bharat Goel | 2024-05-02 | View Spectrum |
| Species |
---|
Species of Origin | Not Available |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as isoflavones. These are polycyclic compounds containing a 2-isoflavene skeleton which bears a ketone group at the C4 carbon atom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Phenylpropanoids and polyketides |
---|
Class | Isoflavonoids |
---|
Sub Class | Isoflav-2-enes |
---|
Direct Parent | Isoflavones |
---|
Alternative Parents | |
---|
Substituents | - Isoflavone
- Chromone
- Benzopyran
- 1-benzopyran
- Alkyl aryl ether
- Pyranone
- Monocyclic benzene moiety
- Pyran
- Benzenoid
- Heteroaromatic compound
- Oxacycle
- Ether
- Organoheterocyclic compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Bae M, Woo M, Kusuma IW, Arung ET, Yang CH, Kim YU: Inhibitory effects of isoflavonoids on rat prostate testosterone 5alpha-reductase. J Acupunct Meridian Stud. 2012 Dec;5(6):319-22. doi: 10.1016/j.jams.2012.07.022. Epub 2012 Aug 9. [PubMed:23265084 ]
- Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, Gennari C, Reginster JY: Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA. 2001 Mar 21;285(11):1482-8. doi: 10.1001/jama.285.11.1482. [PubMed:11255425 ]
- Yao J, Zhang J, Hou JF: Effects of ipriflavone on caged layer bone metabolism in vitro and in vivo. Poult Sci. 2007 Mar;86(3):503-7. doi: 10.1093/ps/86.3.503. [PubMed:17297162 ]
- Yun C, Ding L, Leng Y, Zhu H, Wen A, Yang L: Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study. Biomed Chromatogr. 2012 Jan;26(1):123-8. doi: 10.1002/bmc.1641. Epub 2011 May 19. [PubMed:21594876 ]
- Xiao Z, Huang C, Wu J, Sun L, Hao W, Leung LK, Huang J: The neuroprotective effects of ipriflavone against H (2)O (2) and amyloid beta induced toxicity in human neuroblastoma SH-SY5Y cells. Eur J Pharmacol. 2013 Dec 5;721(1-3):286-93. doi: 10.1016/j.ejphar.2013.09.023. Epub 2013 Sep 29. [PubMed:24084576 ]
|
---|